Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists
Rebeca, T.; Giselle, P.; Litchman, G.H..; Rigel, D.S..
Journal of Drugs in Dermatology Jdd 18(10): 980-984
2019
ISSN/ISBN: 1545-9616 PMID: 31584775 Document Number: 17963
Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is increasing likely due to improved detection and a growing elderly population. Although the prognosis of cSCC is excellent with complete surgical excision, many patients who go on to develop metastasis are initially classified as low-risk. The most commonly used staging systems, American Joint Committee on Cancer (AJCC) and Brigham Women's Hospital (BWH), have low sensitivity and low positive predictive value for predicting metastasis. A gene expression profile test (cSCC-GEP) is in development to identify patients with cSCC at high risk for metastasis and death.
Document emailed within 1 workday
